CEACAM5 and colorectal carcinoma: Importantly, this combination of miRNAs can discriminate early stages of cancer with small tumors from the normal control group, indicating that a panel of plasma miRNA markers offers an advantage over current CRC screening tools such as CEA and FOBT.